drugset / Trial / NCT00697567

Evaluation of Immunogenicity, Reactogenicity and Safety of Herpes Simplex (gD) Candidate Vaccine With/Without Adjuvant

NCT00697567

Phase 2 Completed 80 enrolled GlaxoSmithKline
RandomizedParallel-groupDouble-blindPrevention

Summary

The purpose of the phase IIa study in healthy HSV seropositive and HSV seronegative adults is to evaluate the immunogenicity, reactogenicity and safety of herpes simplex (gD) candidate vaccine with or without adjuvant administered according to a 0, 1, 6 month schedule.

Timeline

Start
1992-09
Primary completion
1997-12
Completion
1997-12

Drugs

EvaluationDrugModalityDoseRoute
Subject GSK208141 Vaccine Intramuscular

Indications

No indication recorded.